SECURITIES PURCHASE AGREEMENT This SECURITIESPURCHASEAGREEMENT (this“Agreement”),datedasofFebruary 27,2019,isenteredintobyandbetween PARALLAXHEALTHSCIENCES,INC.,aNevada corporation(the“Company”),andEMAFinancial,LLC,aDelawarelimitedliabilitycompany (the “Purchaser”). WHEREAS,subjecttothetermsandconditionssetforthinthisAgreementandpursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act” or “1933 Act”), and Rule 506 promulgated thereunder by the United States Securities and Exchange Commission (the “SEC”), the Company desires to issue and sell to the Purchaser, and the Purchaser desires to purchase from the Companya 12% Convertible Note of the Company, in the form attached hereto as  Exhibit  A,  in  the  principal  amount  of  $111,000.00  (together  with  any  note(s)  issued  in replacement thereof or as interest thereon or otherwise with respect thereto in accordance with the terms  thereof,the  “Note”),  convertible  intoshares  (“ConversionShares”)of  commonstock, $0.001 par value per share (the “Common Stock”), of the Company, upon the terms and subject to the limitations and conditions set forth in such Note. NOW,THEREFORE,INCONSIDERATIONofthemutualcovenantscontainedinthis Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows: 1.   Purchase and Sale of Note.  a) PurchaseofNote.OntheClosingDate(asdefinedbelow),theCompany shall issue and sell to the Purchaser, and thePurchaser agrees to purchase from the Company, the Note for an aggregate purchase price of $104,340.00 (“Purchase Price”). Further, Companyshall issue warrants to Buyer to purchase 300,000 shares of common stock (the “Warrant”).  b) FormofPayment.OntheClosingDate(i)thePurchasershallpaythe PurchasePricebywiretransferofimmediatelyavailablefundstotheCompany,inaccordance withtheCompany’swrittenwiringinstructions,simultaneouslywithdeliveryoftheNote,and (ii)  the  Companyshall  deliver  such  Note  duly  executed  on  behalf  of  the  Company  to  the Purchaser, simultaneously with delivery of such Purchase Price.  c) ClosingDate.Subjecttothesatisfaction(orwrittenwaiver)ofthe conditionstheretosetforthinSection8andSection9below,theclosingofthetransactions contemplatedby thisAgreement(the“Closing”)shalloccuronthefirstbusinessday following the date hereof or such other mutually agreed upon time (the “Closing Date”) 2.   Purchaser’s   Representations   and   Warranties. The   Purchaser   represents   and warrants to the Company that:  a) InvestmentPurpose.PurchaserisacquiringtheNote,theWarrant,andthe ConversionShares  (collectively,the  “Securities”)  forits  own  account  andnot  withaview towards,orforresaleinconnectionwith,thepublicsaleordistributionthereofinviolationof applicablesecuritieslaws;provided,however,bymakingtherepresentationsherein,Purchaser doesnotagree,ormakeanyrepresentationorwarranty,toholdanyoftheSecuritiesforany 1 SPA – PRLX, T1, 2019-02-27  minimum or other specific term and reserves theright to dispose of the Securities at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act.  The Purchaser  is  acquiring  the  Securities  hereunder  in  the  ordinary  course  of  its  business.  The Purchaserdoesnotpresentlyhaveanyagreementorunderstanding,directlyorindirectly,with any person to distribute any of the Securities in violation of applicable securities laws.  b) AccreditedInvestorStatus.ThePurchaserisan“accreditedinvestor”asthat term is defined in Rule 501(a) of Regulation D (an “Accredited Investor”). 3.   Representations  and  Warranties  of  the  Company.  Except  as  disclosed  by  the CompanyinthepubliclyfiledSECDocumentstheCompanyrepresentsandwarrantstothe Purchaser, as of the date hereof and the Closing Date, that:  a) Organization and Qualification. The Company and each of its Subsidiaries (as defined below), if any, is a corporation duly organized, validly existing and in good standing underthelawsofthejurisdictioninwhichitisincorporated,withfullpowerandauthority (corporate and other) toown, lease, useand operate its properties and to carry on its business as andwherenowowned,leased,used, operated and conducted.TheSECDocuments setforth alist of all of theSubsidiariesof the Company andthejurisdiction in which each is incorporated The CompanyandeachofitsSubsidiariesisdulyqualifiedasaforeigncorporationtodobusinessand is in good standingin everyjurisdiction in which its ownership or use of propertyor the nature of the business conducted byit makes such qualification necessaryexcept where the failure to be so qualifiedoringoodstandingwouldnothaveaMaterialAdverseEffect.“MaterialAdverse Effect” means any material adverse effect on the business, operations, assets, financial condition orprospectsoftheCompany oritsSubsidiaries,ifany,takenasawhole,oronthetransactions contemplated  herebyor  bythe  agreements  or  instruments  to  be  entered  into  in  connection herewith.“Subsidiaries”meansanycorporationorotherorganization,whetherincorporatedor unincorporated,inwhichtheCompanyowns,directlyorindirectly,anyequityorotherownership interest.  b) Authorization;Enforcement.(i)TheCompanyhasallrequisitecorporate powerand authority toenter into andperform this Agreement, theNote,and the Warrant and to consummatethetransactionscontemplatedherebyandtherebyandtoissuetheSecurities,in accordance with theterms hereof andthereof, (ii)the execution and delivery of this Agreement, theNote,andtheWarrantbytheCompanyandtheconsummationbyitofthetransactions contemplatedherebyandthereby(includingwithoutlimitation,theissuanceoftheNote,and WarrantandtheissuanceandreservationforissuanceoftheConversionShares,andWarrant Shares (as defined in the Warrant) issuable upon conversion and exercise thereof) have been duly authorizedbytheCompany’sBoardofDirectorsandnofurtherconsentorauthorizationofthe Company,itsBoardofDirectors,oritsshareholdersisrequired,(iii)thisAgreementhasbeen dulyexecutedanddeliveredbytheCompanybyitsauthorizedrepresentative,andsuchauthorized representative is the true and official representative with authorityto sign this Agreement and the otherdocumentsexecutedinconnectionherewithandbindtheCompanyaccordingly,and(iv) this  Agreement  constitutes,anduponexecutionanddeliverybytheCompanyoftheNote, Warrant, and each of such instruments will constitute, a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms. 2 SPA – PRLX, T1, 2019-02-27    c) Capitalization.Asofthedatehereof,theauthorizedcapitalstockofthe Company,andnumberofsharesissuedandoutstanding,isassetforthintheCompany’smost recentperiodicreportfiledwiththeSEC.ExceptasdisclosedintheSECDocumentsnoshares arereservedforissuancepursuanttotheCompany’sstockoptionplans.Exceptasdisclosedin the SEC Documents no shares are reserved for issuance pursuant to securities exercisable for, or convertible into or exchangeable for shares of Common Stock. All of such outstanding shares of capitalstockare,oruponissuancewillbe,dulyauthorized,validlyissued,fullypaidandnon- assessable.NosharesofcapitalstockoftheCompanyaresubjecttopreemptiverightsorany othersimilarrightsoftheshareholdersoftheCompanyoranyliensorencumbrancesimposed through theactions or failure to act of the Company. As of the effective date of this Agreement, andexceptasdisclosedintheSECDocuments,(i)therearenooutstandingoptions,warrants, scrip,rightstosubscribefor,puts,calls,rightsoffirstrefusal,agreements,understandings,claims orothercommitmentsorrightsofanycharacterwhatsoeverrelatingto,orsecurities,notesor rights convertible into or exchangeable for any shares of capital stock of the Company or any of itsSubsidiaries,orarrangementsbywhichtheCompanyoranyofitsSubsidiariesisormay becomeboundtoissueadditionalsharesofcapitalstockoftheCompanyoranyofitsSubsidiaries, (ii) there are no agreements or arrangements under which the Companyor any of its Subsidiaries isobligatedtoregisterthesaleofany ofitsortheirsecuritiesunderthe1933Actand(iii)there are  no  anti-dilution  or  price  adjustment  provisions  contained  in  anysecurity  issued  by  the Company (or in any agreement providing rights tosecurity holders) that will be triggered by the issuanceofanyoftheSecurities.TheCompanyhasfurnishedtothePurchasertrueandcorrect copiesoftheCompany’sCertificateorArticlesofIncorporationasineffectonthedatehereof (“FormationDocuments”),theCompany’sBy-laws,asineffectonthedatehereof(the“By- laws”),andthetermsofallsecuritiesconvertibleintoorexercisableforCommonStockofthe Company and the material rights of the holders thereof in respect thereto.  d) IssuanceofShares.The ConversionShares,andWarrantShares(asdefined in the Warrant)are duly authorized and reserved for issuanceand, uponconversion of theNote, and exercise of the Warrant respectively, as the case may be, in accordance with their respective terms, will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances with respect to the issuethereof and shall not be subjectto preemptiverights orothersimilarrightsofshareholdersoftheCompanyandwillnotimposepersonalliabilityupon the holder thereof.  e) AcknowledgmentofDilution.TheCompany’sexecutiveofficersand directorsunderstandthe natureoftheSecuritiesbeingsoldherebyandrecognizethattheissuance of the Securities will have a potential dilutive effect on the equityholdings of other holders of the Company’sequityorrightstoreceiveequityoftheCompany.  TheBoardofDirectorsofthe Companyhas concluded, in its good faith business judgment that the issuance of the Securities is in the best interests of the Company.  The Companyspecificallyacknowledges that its obligation toissuetheConversionSharesuponconversionoftheNotesisbindingupontheCompany and enforceable regardless of the dilution such issuance mayhave on the ownership interests of other stockholders of the Company or parties entitled to receive equity of the Company.  f) No Conflicts. The execution, delivery and performance of this Agreement, theNote,andtheWarrantbytheCompanyandtheconsummationbytheCompanyofthe transactionscontemplatedherebyandthereby(including,withoutlimitation,theissuancesand 3 SPA – PRLX, T1, 2019-02-27  reservations for issuance of the Conversion Shares, and Warrant Shares) will not (i) conflict with or result in a violation of anyprovision of the Formation Documents or By-laws, or (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with notice or lapse of time or both could become a default) under, or give to others anyrights of termination, amendment, acceleration or cancellation of, anyagreement, indenture, patent, patent licenseorinstrumenttowhichtheCompanyoranyofitsSubsidiariesisapartyandthatisnot filedasanSECDocumentorotherdocumentfiledwiththeSEC,or(iii)resultinaviolationof anylaw,rule,regulation,order,judgmentordecree(includingfederalandstatesecuritieslaws and regulations and regulations of anyself-regulatory organizations to which the Companyor its securitiesaresubject)applicabletotheCompanyoranyofitsSubsidiariesorbywhichany property or asset of the Company or any of its Subsidiaries is bound or affected (except for such conflicts,  defaults,  terminations,  amendments,  accelerations,  cancellations  and  violations  as would  not,  individually  or  in  the  aggregate,  have  a  Material  Adverse  Effect).  Neither  the Companynor anyof itsSubsidiariesisinviolationofitsFormationDocuments,By-lawsorother organizational documents and neither the Company norany ofits Subsidiaries is in default (and noeventhasoccurredwhichwithnoticeorlapse oftimeorbothcould put theCompany orany ofitsSubsidiariesindefault)under,andneithertheCompanynoranyofitsSubsidiarieshastaken anyactionorfailedtotakeanyactionthatwouldgivetoothersanyrightsoftermination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Companyor anyof its Subsidiaries is a party or by which anyproperty or assets of the Company or  any  of  its  Subsidiaries  is  bound  or  affected,  except  for  possible  defaults  as  would  not, individuallyor in the aggregate, have a Material Adverse Effect. The businesses of the Company anditsSubsidiaries,ifany,arenotbeingconducted,andshallnotbeconductedsolongasthe PurchaserownsanyoftheSecurities,inviolationofanylaw,ordinanceorregulationofany governmentalentity.ExceptasspecificallycontemplatedbythisAgreementandasrequired underthe1933Actandanyapplicablestatesecuritieslaws,theCompanyisnotrequiredtoobtain any  consent,  authorization  or  order  of,  or  make  any  filing  or  registration  with,  any  court, governmentalagency,regulatoryagency,self-regulatoryorganizationorstockmarketoranythird partyin orderforittoexecute,deliver orperform anyofitsobligationsunderthisAgreementand theNoteinaccordancewiththetermshereoforthereofortoissueandselltheSecuritiesin accordancewiththetermshereofandthereofandtoissuetheConversionShares.Allconsents, authorizations, orders, filings and registrations which the Companyis required to obtain pursuant totheprecedingsentencehavebeenobtainedoreffectedonorpriortothedatehereof.The CompanyisnotinviolationofthelistingrequirementsoftheOver-the-CounterBulletinBoard (the “OTCBB”), or OTCQB, anddoes not reasonably anticipate that theCommon Stock will be delisted bythe OTCBB, or OTCQB, in the foreseeable future. The Companyand its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.  g) SEC Documents; Financial Statements. The Company has filed all reports, schedules,forms,statementsandotherdocumentsrequiredtobefiledby itwiththe SEC(allof the  foregoing  filed  prior  to  the  date  hereof  and  all  exhibits  included  therein  and  financial statementsandschedulestheretoanddocuments(otherthanexhibitstosuchdocuments) incorporated byreference therein, being hereinafter referred to herein as the “SEC Documents”). Upon written request theCompany will deliver to the Purchaser trueand complete copies of the SECDocuments,exceptforsuchexhibitsandincorporateddocuments.Asoftheirrespective dates,  the  SEC  Documents  complied  in  all  material  respects  with  the  requirements  of  the Securities Exchange Act of 1934, as amended (“1934 Act” or “ExchangeAct”), and none of the 4 SPA – PRLX, T1, 2019-02-27  SECDocuments,atthetimetheywerefiledwiththeSEC,containedanyuntruestatementofa material fact or omitted to state a material fact required to be stated therein or necessary in order tomakethestatementstherein,inlightofthecircumstancesunderwhichtheyweremade,not misleading.Noneofthestatementsmadeinany suchSECDocumentsis,orhasbeen,required tobeamendedorupdatedunderapplicablelaw(exceptforsuchstatementsashavebeenamended or updated in subsequentfilings prior the date hereof). As of their respective dates, the financial statementsoftheCompany includedintheSECDocumentscompliedastoforminallmaterial respectswithapplicableaccountingrequirementsandthepublishedrulesandregulationsofthe SECwithrespectthereto.Suchfinancialstatementshavebeenpreparedinaccordancewith UnitedStatesgenerallyacceptedaccountingprinciples,consistently applied,duringtheperiods involvedandfairlypresentinallmaterialrespectstheconsolidatedfinancialpositionofthe Company and its consolidated Subsidiaries as of the dates thereof and the consolidated results of theiroperationsandcashflowsfortheperiodsthenended(subject,inthecaseofunaudited statements, to normal year-end audit adjustments). Except as set forth in the financial statements oftheCompany includedintheSECDocuments,theCompany hasnoliabilities,contingentor otherwise,otherthan (i)liabilitiesincurredin theordinarycourse ofbusiness,and(ii) obligations undercontractsandcommitmentsincurredintheordinarycourseofbusinessandnotrequired undergenerallyacceptedaccountingprinciplestobereflectedinsuchfinancialstatements,which, individuallyor in the aggregate, are not material to the financial condition or operating results of the Company. The Company is subject to the reporting requirements of the 1934 Act.  h) AbsenceofCertainChanges.ExceptasdisclosedintheSECfilings,there hasbeennomaterialadversechangeandnomaterialadversedevelopmentintheassets,liabilities, business, properties, operations, financial condition, results of operations, prospects or 1934 Act reporting status of the Company or any of its Subsidiaries.  i) AbsenceofLitigation.ExceptasdisclosedintheSECfilings,thereisno action,suit,claim,proceeding,inquiryorinvestigationbeforeorbyanycourt,publicboard, governmentagency,self-regulatoryorganizationorbodypendingor,totheknowledgeofthe CompanyoranyofitsSubsidiaries,threatenedagainstoraffectingtheCompanyoranyofits Subsidiaries,ortheirofficersordirectorsintheircapacityassuch,thatcouldhaveaMaterial AdverseEffect.Thepublicfilingscontainacompletelistandsummarydescriptionofanypending or, to the knowledge of the Company, threatened proceeding against or affectingthe Companyor any ofitsSubsidiaries,withoutregardtowhetheritwouldhaveaMaterialAdverseEffect.The Companyand its Subsidiaries are unaware of anyfacts or circumstances which might give rise to any of the foregoing.  j) Patents,Copyrights,etc. TheCompanyandeachofitsSubsidiariesownsor possessestherequisitelicensesorrightstouseallpatents,patentapplications,patentrights, inventions,know-how,tradesecrets,trademarks,trademarkapplications,servicemarks,service names, trade names and copyrights (“Intellectual Property”) necessary to enable it to conduct its businessasnowoperated(and,aspresentlycontemplatedtobeoperatedinthefuture);thereis noclaimoractionbyanypersonpertainingto,orproceedingpending,ortotheCompany’s knowledgethreatened,whichchallengesthe right oftheCompanyorof aSubsidiarywithrespect toanyIntellectualProperty necessary toenableittoconductitsbusinessasnowoperated(and, as presently contemplated to be operated in the future); to the best of the Company’s knowledge, theCompany’soritsSubsidiaries’currentandintendedproducts,servicesandprocessesdonot 5 SPA – PRLX, T1, 2019-02-27  infringeonanyIntellectualPropertyorotherrightsheldbyanypersonand/orentity;andthe Companyis unaware of anyfacts or circumstances which might give rise to anyof the foregoing. The Companyand each of its Subsidiaries have taken reasonable securitymeasures to protect the secrecy, confidentiality and value of their Intellectual Property.  k) No Materially Adverse Contracts, Etc. Neither theCompany nor any of its Subsidiariesissubjecttoanycharter,corporateorotherlegalrestriction,oranyjudgment,decree, order,ruleorregulationwhichinthejudgmentoftheCompany’sofficershasorisexpectedin the future to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is aparty toany contractoragreementwhichinthejudgmentoftheCompany’sofficershasoris expected to have a Material Adverse Effect.  l) Disclosure. No event or circumstance has occurred or exists with respect to theCompany orany ofitsSubsidiariesoritsortheirbusiness,properties,prospects,operations orfinancial conditions,which,under applicablelaw,ruleor regulation,requirespublicdisclosure or announcement by the Company but which has not been so publicly announced or disclosed.  m) Brokers.TheCompanyherebyrepresentsandwarrantsthatithasnothired, retainedordealtwithanybroker,finder,consultant,person,firmorcorporation(“Broker”)in connectionwiththenegotiation,executionordeliveryofthisAgreementorthetransactions contemplatedhereunder.TheCompanycovenantsandagreesthatshouldanyclaimbemade againstPurchaserforanycommissionorothercompensationbytheBroker,baseduponthe Company’sengagementofsuchpersoninconnectionwiththistransaction,theCompanyshall indemnify, defend and hold Purchaser harmless from and against any and all damages, expenses (includingattorneys’feesanddisbursements)andliabilityarisingfromsuchclaim.TheCompany shall pay the commission of the Broker, to the attention of the Broker, pursuant to their separate agreement(s) between the Company and the Broker.  n) Permits;  Compliance.  The  Company  and  each  of  its  Subsidiaries  is  in possession  of  all  franchises,  grants,  authorizations,  licenses,  permits,  easements,  variances, exemptions,consents,certificates,approvalsandordersnecessarytoown,leaseandoperateits propertiesand tocarry on its business asit is now being conducted(collectively,the“Company Permits”),andthereisnoactionpendingor,totheknowledgeoftheCompany,threatened regardingsuspensionorcancellationofany oftheCompany Permits.NeithertheCompany nor anyofitsSubsidiariesisinconflictwith,orindefaultorviolationof,anyoftheCompanyPermits, exceptforanysuchconflicts,defaultsorviolationswhich,individuallyorintheaggregate,would not reasonably be expected to have a Material Adverse Effect. Since December 31, 2017, neither theCompanynoranyofitsSubsidiarieshasreceivedanynotificationwithrespecttopossible conflicts,defaultsorviolationsofapplicablelaws,exceptfornoticesrelatingtopossibleconflicts, defaults or violations, which conflicts, defaults orviolations would not have a Material Adverse Effect.  o) Insurance.TheCompanyanditsSubsidiariesareinsuredbyinsurersof recognized financial responsibilityagainst such losses and risks and in such coverage, amounts asareprudentandcustomaryinthebusinessesinwhichtheCompanyisengaged,including, but not limited to, directors and officer’s insurance coverage with coverage amounts that are at least equal to theaggregate PurchasePrice.Neither theCompany norany Subsidiary hasany 6 SPA – PRLX, T1, 2019-02-27


reasontobelievethatitwillnotbeabletorenewitsexistinginsurancecoverageasandwhen such coverage expires orto obtain similar coveragefrom similar insurersas may be necessary to continue its business without a significant increase in cost.  p) No “Shell”. As of the date of this AgreementtheCompany is anoperating companyand, either (i) is not or has never been a “shell issuer” as defined in Rule 144(i)(2) or (ii) at least 12 months have passed since the Company filed Form 10 Type information indicating it is nota“shellissuer”(andsupportingtheclaimthatitisnolongerashellcompany),filedall requiredreportsforatleasttwelveconsecutivemonthsafterthefilingoftherespectiveForm10 information, and has therefore complied with Rule 144(i)(2).  q) BadActor.NoofficerordirectoroftheCompanywouldbedisqualified under Rule 506(d) of the Securities Act as amended on the basis of being a “bad actor”.  r) Acknowledgement Regarding Purchaser’s Trading Activity. NotwithstandinganythinginthisAgreementorelsewheretothecontraryitisunderstoodand acknowledgedbytheCompanythat:(i)thePurchaserhasnotbeenaskedbytheCompanytoagree, nor hasany Purchaseragreed, to desist from purchasing or selling, securities of theCompany, or “derivative” securities based on securities issued bythe Companyor to hold the Securities for any specified term; (ii) each Purchaser shall not be deemed to have anyaffiliation with or control over any arm’s length counter-party in any “derivative” transaction. s)Sarbanes-OxleyAct. The Companyand each Subsidiaryis in material compliance with all applicable requirements of the Sarbanes-OxleyAct of 2002 that are effective as of the date hereof,andallapplicablerulesandregulationspromulgatedbytheSECthereunderthat are effective as of the date hereof. 4.   COVENANTS.  a) Best Efforts. The parties shall use their best efforts to satisfytimelyeach of the conditions described in Section 6 and 7 of this Agreement.  b) FormD;BlueSkyLaws.TheCompanyagreeswhenapplicabletotimely fileaFormDwithrespecttotheSecuritiesasrequiredunderRegulationDandtoprovidea copy thereoftothePurchaserpromptly aftersuchfiling.TheCompany shall,onorbeforethe ClosingDate,takesuchactionastheCompanyshallreasonablydetermineisnecessaryto qualify  the  Securities  for  sale  to  the  Purchaser  at  the  applicable  closing  pursuant  to  this Agreement under applicable securities or “blue sky”laws of the states of the United States (or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken to the Purchaser on or prior to the Closing Date.  c) Use of Proceeds.The Company shall use the proceedsfrom the saleof the Securities for general corporate and administrative purposes. 7 SPA – PRLX, T1, 2019-02-27    d) Financial Information.UponwrittenrequestofthePurchaser,theCompany agreestowithin(3)threedaysofthewrittenrequestsendormakeavailablethefollowing reportsfiledwiththeSECorOTCMarketsGrouptothePurchaser:acopyofitsAnnualReport and its QuarterlyReports and anySupplemental Reports; (ii) copies of all press releases issued by the Company orany of its Subsidiaries; and (iii) copies of any noticesor other information theCompanymakesavailableorgivestosuchshareholders.Notwithstandingtheforegoing, the Companyshall not disclose anymaterial nonpublicinformation to the Purchaser without its consentunlesssuchinformationisdisclosedtothepublicpriortoorpromptly following such disclosure to the Purchaser.  e) Listing.TheCompanywillobtainand,solongasthePurchaserownsany oftheSecurities,maintainthelistingandtradingofitsCommonStockontheOTCBB,and OTCQB, or anyequivalent replacement exchange, the NASDAQ Stock Market (“NASDAQ”), theNewYorkStockExchange (“NYSE”),orthe NYSEMKT, f/k/aAmericanStock Exchange (“AMEX”),andwillcomplyinallrespectswiththeCompany’sreporting,filingandother obligationsunderthebylawsorrulesoftheFinancialIndustryRegulatoryAuthority(“FINRA”) andsuchexchanges,asapplicable.TheCompanyshallpromptlyprovidetothePurchaser copiesofany noticesitreceivesfromtheSEC,OTCMarketsGroupandany otherexchanges orquotationsystems  on  whichtheCommonStockis  thenlistedregardingthe  continued eligibilityof the Common Stock for listing on such exchanges and quotation systems, provided that it shall not provide any notices constituting material nonpublic information.If at any time whiletheNoteisoutstandingtheCompanyfailstomaintainthelistingandtradingandofits Common Stock, or fails in anywayto complywith the Company’s reporting/ filing obligations suchfailure(s)willresultinliquidateddamagesoffifteenthousanddollars($15,000),being immediately due andpayable to Holder at itselection in the form of cash payment oraddition to the balance of the Note.  f) CorporateExistence.Solong  asthe  Purchaserbeneficially  ownsany Securities,theCompany  shallmaintainitscorporateexistenceandshallnotsellallor substantiallyalloftheCompany’sassets,exceptintheeventofamergerorconsolidationor sale of all or substantially all of the Company’s assets, where the surviving or successor entity in such transaction (i) assumes the Company’s obligations hereunder and under the agreements andinstrumentsenteredintoinconnectionherewithand(ii)isapubliclytradedcorporation whose Common Stock is listed for trading on NASDAQ, NYSE or AMEX.  g) NoIntegration.TheCompanyshallnotmakeanyoffersorsalesofany security(otherthantheSecurities)undercircumstancesthatwouldrequireregistrationofthe Securitiesbeingofferedorsoldhereunderunderthe1933Actorcausetheofferingofthe Securities to be integrated with anyother offeringof securities bythe Companyfor the purpose of any stockholder approval provision applicable to the Company or its securities.  h) SecuritiesLawsDisclosure;Publicity.   TheCompanyshallcomplywith applicablesecuritieslawsby filingaCurrentReportonForm8-K,withinfour(4)TradingDays followingthedatehereof,disclosingallthematerialtermsofthetransactionscontemplatedhereby.  i) Non-PublicInformation.Exceptwithrespecttothematerialtermsand conditionsofthetransactionscontemplatedbythisAgreement,theCompanycovenantsandagrees 8 SPA – PRLX, T1, 2019-02-27  that neither it nor any other personacting on its behalf will provide the Purchaser or its agents or counselwithanyinformationthattheCompanybelievesconstitutesmaterialnon-public information, unless prior thereto the Purchaser shall have executed a written agreement regarding theconfidentiality anduseofsuchinformation.TheCompany understandsandconfirmsthat the Purchasershallberelying ontheforegoing covenantineffecting transactionsinsecuritiesofthe Company.  j) Subsidiaries.So long as the Note remainsoutstanding, the Company shall not transfer anyassets or rights to anyof its subsidiaries or permit anyof its subsidiaries to engage inanysignificantbusinessoroperations,whethersuchsubsidiariesarecurrentlyexistingor hereafter created.  k) Insurance.SolongastheNoteremainsoutstanding,theCompany andits Subsidiaries shall maintain in full force and effect insurance reasonablybelieved bythe Company to be adequate coverage (a) on all assets and activities, covering property loss or damage and loss ofincomeby fireorotherhazardsorcasualty,and(b)againstallliabilities,claimsandrisksfor whichitiscustomaryforcompaniessimilarlysituatedtotheCompanytoinsure,includingwithout limitationapplicableproductliabilityinsurance,requiredworkmen’scompensationinsurance,and otherinsurancecoveringinjuryordamagetopersonsorproperty,butexcludingdirectorsand officers  insurancecoverage.TheCompanyshall  promptlyfurnishor  causetobe  furnished evidence of such insurance to the Purchaser, in form and substance reasonably satisfactory to the Purchaser  l) ROFR.  At any time while the Note is outstanding, the Company desires to borrowfunds,raiseadditionalcapitaland/orissueadditionalpromissorynotesconvertibleinto sharesofsecuritiesoftheCompany(a“ProspectiveFinancing”),thePurchasershallhavetheright of first refusal to participate in the Prospective Financing, and the Company shall provide written notice containing the terms of suchProspectiveFinancing (the“ROFR Notice”) tothe Purchaser prior to effectuating any such transaction.  The ROFR Notice shall specify all of the key terms of theProspectiveFinancing,including,butnotlimitedto,theproposedinvestmentamount,the proposed rate of interest, the proposed conversion price, the proposed term of the investment, the typeandnumberofsecuritiestobesoldandany andallotherrelevantterms,eachasapplicable. Upon  Purchaser’s  receipt  of  the  ROFR  Notice,  Purchaser  shall  have  the  exclusive  right  to participateinsuchProspectiveFinancing(s),uponthetermsspecifiedintheROFRNotice,by sending written notice to the Company within seven (7) business days after Purchaser’s receipt of the ROFR Notice.In theevent Purchaser fails toexercise its right offirstrefusalwith respect to anROFRNoticewithinthetimesetforthabove,Purchasershallbedeemedtohavewaivedits rightoffirstrefusalwithrespecttosuchProspectiveFinancing,providedthatitshallretainsuch right  with  respect  toanyfutureProspectiveFinancing.Notwithstandinganythingcontained herein,  the  Company  shall  not  furnish  any  material  non-public  information  concerning  the CompanywithoutthePurchaser’spriorwrittenconsent,andshallinitiallyonlyindicatetothe Purchaser  that  the  Companycontemplates  a  financing.    Notwithstanding  anything  contained herein,innoeventshallthePurchaserbeentitledtopurchaseanysecuritieswhichwouldcause thesumof(1)thenumberofsharesofCommonStockbeneficially ownedby thePurchaserand itsaffiliates(otherthansharesofCommonStockwhichmaybedeemedbeneficiallyowned throughtheownershipoftheunconvertedportionoftheNoteortheunexercisedorunconverted 9 SPA – PRLX, T1, 2019-02-27  portionofanyothersecurityoftheCompanysubjecttoalimitationonconversionorexercise analogoustothelimitationscontainedherein)and(2)thenumberofsharesofdirectlyorindirectly purchasableunderthisSection,toexceed4.9%oftheoutstandingsharesofCommonStock(or 9.99%ofthetotalissuedCommonStockoftheCompany  ifspecifiedby  Purchaserand accompanied with applicable documentation such as any Amendment made to this Agreement or the Note).  m) FutureFinancings:ExceptforsalesorissuancestoCompanyemployees, andmembersoftheCompany’sboardofdirectors,fromthedatehereofuntilsuchtimeasthe PurchasernolongerholdsanyoftheSecurities,intheeventtheCompanyissuesorsellsanyshares of Common Stock or securities directly or indirectly convertible into or exercisableforCommon Stock (“Common StockEquivalents”) or amends the transaction documents relatingto anysale or issuance of Common Stock or Common Stock Equivalents, and the Purchaser reasonablybelieves thatthetermsandconditionsthereunderaremorefavorabletosuchinvestorsasthetermsand conditions granted under this Agreement, Note or any document provided by the Purchaser to the Companyrelatingto anysale or issuance of Common Stock (the “Transaction Documents”), upon noticetotheCompanybysuchPurchaser,theTransactionDocumentsshallbedeemed automaticallyamendedsoastogivethePurchaserthebenefitofsuchmorefavorabletermsor conditions.PromptlyfollowingarequesttotheCompanytheCompanyshallprovidePurchaser withallexecutedtransactiondocumentsrelatingtoanysuchsaleorissueofCommonStockor CommonStockEquivalents.Companyshall   deliveracknowledgmentofsuchautomatic amendmenttotheTransactionDocumentstoPurchaserinformandsubstancereasonably satisfactorytothePurchaser(the“Acknowledgment”)withinthree(3)businessdaysof Company’sreceiptofrequestfromPurchaser(the“Deadline”),providedthatCompany’sfailure to timely provide the Acknowledgement shall not affect the automatic amendments contemplated hereby.IftheAcknowledgementisnotdeliveredbytheDeadline,Companyshallpaytothe Purchaser$1000.00perday incash,foreachday beyondtheDeadlinethattheCompany failsto deliversuchAcknowledgementsuchcashamountshallbepaidtoHolderbythefirstdayofthe month following the month in which it has accrued or, at the option of the Holder, shall be added totheprincipalamountoftheNote,inwhicheventinterestshallaccruethereoninaccordancewith thetermsoftheNoteandsuchadditionalprincipalamountshallbeconvertibleintoCommon Stock in accordance with the terms of the Note.  n) Piggyback  Registration  Rights.  Borrower  shall  include  on  the:  (i)  next registrationstatementBorrowerfileswiththeSEC;or(ii)onthesubsequentregistrationstatement ifsuchregistrationstatementiswithdrawn),or,(iii)amendaregistrationstatementpreviously filed, but not effective as of the Issue Date all shares issuable upon conversion of the Note. Failure todosowillresultinliquidateddamagesoffiftypercent(50%)oftheoutstandingprincipalamount oftheNote,butnotlessthantwenty-fivethousanddollars($25,000),beingimmediately dueand payabletoHolderatitselectionintheformofcashpaymentoradditiontothebalanceoftheNote.  o) SubsequentFinancings.Notwithstandinganythingcontainedherein,ifat anytimewhilethisNoteisoutstandingtheCompanyentersintoanycapitalraisingtransaction, includingwithoutlimitationanequity linetransaction,aloantransactionorthesaleofsharesof CommonStockorsecuritiesconvertibleintoorexercisableorexchangeableforCommonStock, whether  or  not  permitted  under  the  Transaction  Documents  (“Subsequent  Financing”),  then 10 SPA – PRLX, T1, 2019-02-27  followingtheclosingofeachsuchSubsequentFinancingtheHolderinitssoleandabsolute discretionmaycompeltheCompanytoredeemuptotheentireoutstandingbalanceoftheNote fromthegrossproceedstherefrom(“RedemptionAmount”),providedhowever(a)iftheHolder is holding other convertible notes similar to this Note whether issued prior or after theIssue Date of this Note (collectively with this Note, the “Notes”), the Redemption Amountmay be applied to redeem any or all of the Notes specified by the Holder, (b) the Holder shall be notified in writing of the closing ofeach such Subsequent Financing within one (1) day following suchclosing, and (c) the Holder may electnot to exercise its right to such redemption in whole or in part, in which casetheCompanymaynotredeemanyNotesinconnectionwithsuchSubsequentFinancingto theextentsorejected(forclarification,iftheholderelectstorejectanyredemptioninanyinstance, such rejection shall not affect the Holder’s redemption rights hereunder in the future). Further, in theeventthattheHolderdemandsredemptionofaportionorthefullbalanceoftheNotewithin thefirstsix(6)monthsfromNote’sIssueDate,suchRedemptionAmountshallsubjecttothen thenapplicablePrepaymentFactor,asdefinedintheNoteshallbeapplied).   Totheextentthe Company isobligatedtoredeemany portionoftheNotespursuanttothisSectionbutfailstodo so, such default shall constitute an Event of Default under all the Notes.  p) AdditionalInvestmentRight.Purchasershallhavetherightatanytimefrom time to time, as of the date hereof, and until such date when the Note is no longer outstanding, to initssoleandabsolutediscretionpurchaseanadditionalconvertiblepromissorynote,oradditional convertible promissorynotes, from the Companyfor up to a principal amount equal to the amount oftheNotepurchasedhereunder(eacha“SubsequentNote”andcollectivelythe“Subsequent Notes”)onthesametermsandconditionsasapplicabletothepurchaseandsaleoftheNote purchasedonthedatehereofbyPurchaser,andinsubstantiallythesameformandsubstanceas theNoteissuedpursuanttothisAgreement,mutatismutandis,(eacha“SubsequentNotePurchase” and collectively “Subsequent Note Purchases”).  For Purchaser to exercise such Subsequent Note Purchase right,  Purchaser shall deliver  written notice, to the Company (for claritynotice sent via electronic mail shall satisfysuch written notice requirement) electing to exercise such Subsequent Note Purchase right, which notice shall specify the principal amount of the Additional Note to be purchasedby suchPurchaser(“SubsequentNoteAmount”)andthedateonwhichsuchpurchase andsaleshalloccur(“SubsequentNoteClosing”),whichSubsequentNoteClosingshalloccur within five (5)days following such noticeby suchPurchaser, orsuch otherdate mutually agreed upon by the Purchaser and Company. The terms and conditions of anySubsequent Note Purchase shallbeidenticalto thetermsandconditionssetforthinthisAgreementapplicabletothesaleof theNoteon the date hereof,includingwithoutlimitationeach Subsequent Notewillbe inthe form of the Note issued hereto, provided that the MaturityDate thereunder shall be on ninth (9 th) month fromtheSubsequentNote’sissuedate.Further,ifawarranttopurchaseCompany’scommonstock wasissuedpursuanttothisAgreementthenPurchasershallreceiveawarrantintheformasthe sameformandsubstanceasthewarrantissuedpursuanttothisAgreement(“Subsequent Warrant”),providedthattheTerminationDateoftheAdditionalWarrantshallbethefifth(5th) anniversaryfromtheissuedateoftheSubsequentWarrant.OnorpriortoanySubsequentNote Closing(s), the Company and the Purchaser shall, upon Purchaser’s request, execute and deliver a newsecuritiespurchaseagreementwithrespecttotheSubsequentNotePurchase(s)inthesame form and substance as this Agreement (each a “Subsequent Purchase Agreement and collectively “SubsequentPurchaseAgreements”),mutatismutandis,andalltherepresentations,warrants, covenants,indemnitiesandconditionssetforthhereinshallbeincludedandincorporatedwith 11 SPA – PRLX, T1, 2019-02-27  respecttosuchNotePurchase,mutatismutandis.PurchasermayassignitsSubsequentNote Purchase right hereunder to any affiliate of such Purchaser.  q) SubsequentFinancings.Notwithstandinganythingcontainedhereinifat anytimewhilethisNoteisoutstandingtheCompanyentersintoanycapitalraisingtransaction, includingwithoutlimitationanequity linetransaction,aloantransactionorthesaleofsharesof CommonStockorsecuritiesconvertibleintoorexercisableorexchangeableforCommonStock, whetherornotpermittedundertheTransactionDocuments(“SubsequentFinancing”),nomore than five (5) Trading Daysfollowing the closing of each such Subsequent Financing  in Holder’s soleand absolutediscretionatleast 50%of the grossproceedstherefrom (“RedemptionAmount”) shall be paid to the Holder to redeem a portion of the Note’s balance, provided however (a) if the HolderisholdingotherconvertiblenotessimilartothisNoteissuedbythe Company(collectively withthisNote,the“Notes”),theRedemptionAmountshallbeappliedtoredeemtheNotespecified by theHolder,(b)theHoldershallbenotifiedinwritingoftheclosingofeachsuchSubsequent Financingwithinone(1)dayfollowingsuchclosing,and(c)theHoldermayelecttorejectany suchredemptioninwholeorinpart,inwhichcasetheCompanymaynotredeemanyNotesin connectionwithsuchSubsequentFinancingtotheextentsorejected(forclarification,iftheHolder elects  to  reject  anyredemption  in  anyinstance,  such  rejection  shall  not  affect  the  Holder’s redemption rights hereunder in the future). To the extent the Company is obligated to redeem any portionoftheNotespursuanttothisSectionbutfailstodoso,suchdefaultshallconstitutean Event of Default under all the Notes. 5.   TransferAgentInstructions.UponreceiptofadulyexecutedNoticeofConversion, theCompanyshall  issueirrevocableinstructions  to  its  transferagent  to  issuecertificates, registeredinthenameofthePurchaseroritsnominee,fortheConversionSharesinsuch amountsasspecifiedfromtimetotimeby thePurchasertotheCompanyuponconversionof theNote,oranypartthereof,inaccordancewiththetermsthereof(the“IrrevocableTransfer AgentInstructions”).IntheeventthattheCompany proposestoreplaceitstransferagent,the Companyshall  provide,  prior  to  the  effective  date  of  such  replacement,  a  fullyexecuted IrrevocableTransferAgentInstructions  in  aform  as  initially  delivered  pursuant  to  this Agreement and the Securities (including but not limited to the provision to irrevocably reserve sharesofCommonStockintheReservedAmount(asdefinedintheNote))signedbythe successor  transfer  agent  (to  the  Company)  and  the  Company.  Prior  to  registration  of  the Conversion Shares under the 1933 Act or the date on which the Conversion Shares maybe sold pursuanttoRule144withoutanyrestrictionastothenumberofSecuritiesasofaparticular datethatcanthenbeimmediatelysold,allsuchcertificatesshallbeartherestrictivelegend specifiedinSection2(g)ofthisAgreement.TheCompanywarrantsthat:(i)noinstructionother than theIrrevocable Transfer AgentInstructions referred to in this Section 5, and stop transfer instructionstogiveeffecttohereof(inthecaseoftheConversionShares,priortoregistration of the Conversion Shares under the 1933 Act or the date on which the Conversion Shares may besoldpursuanttoRule144withoutanyrestrictionastothenumberofSecuritiesasofa particular date that can then be immediately sold), will be given bythe Company to its transfer agent and that the Securities shall otherwise be freely transferable on the books and records of the Companyas and to the extent provided inthisAgreement and the Note; (ii) it will notdirect its transfer agent not to transfer or delay, impair, and/or hinder its transfer agent in transferring 12 SPA – PRLX, T1, 2019-02-27


(orissuing)(electronicallyorincertificatedform)anycertificateforConversionSharestobe issuedtothePurchaseruponconversionoforotherwisepursuanttotheNoteasandwhen requiredbytheNoteandthisAgreement;and(iii)itwillnotfailtoremove(ordirectitstransfer agentnottoremoveorimpair,delay,and/orhinderitstransferagentfromremoving)any restrictivelegend(ortowithdrawanystoptransferinstructionsinrespectthereof)onany certificateforany ConversionSharesissuedtothe Purchaseruponconversionoforotherwise pursuanttotheNoteasandwhenrequiredbytheNoteandthisAgreement.Nothinginthis Sectionshallaffectinanyway thePurchaser’sobligationsandagreementsetforthinSection 2(g) hereof to complywith all applicable prospectus deliveryrequirements, if any, upon re-sale of the Securities. If the Purchaser provides the Companywith (i) an opinion of counsel in form, substanceandscopecustomaryforopinionsincomparabletransactions,totheeffectthata public sale or transfer of such Securities may be made without registration under the 1933 Act andsuchsaleortransferiseffectedor(ii)the Purchaserprovidesreasonableassurancesthatthe Securities can be sold pursuant to Rule 144, the Company shall permit the transfer, and, in the case  of  the  Conversion  Shares,  promptly  instruct  its  transfer  agent  to  issue  one  or  more certificates,freefromrestrictivelegend,insuchnameandinsuchdenominationsasspecified by the Purchaser.TheCompany acknowledgesthatabreachby itofitsobligationshereunder will  cause  irreparable  harm  to  the  Purchaser,  by  vitiating  the  intent  and  purpose  of  the transactions contemplated hereby. Accordingly, the Companyacknowledges that the remedyat lawforabreachofitsobligationsunderthisSection5maybeinadequateandagrees,inthe eventofabreachorthreatenedbreachby theCompanyoftheprovisionsofthisSection,that thePurchasershallbeentitled,inadditiontoallotheravailableremedies,toaninjunction restraininganybreachandrequiringimmediatetransfer,withoutthenecessityofshowing economic loss and without any bond or other security being required. 6.   Injunction PostingofBond.  IntheeventthePurchasershallelecttoconvertthe Noteoranypartsthereof,theCompanymaynotrefuseconversionorexercisebasedonany claim that Purchaser or anyone associated or affiliated with Purchaser has been engaged in any violationoflaw,orforanyotherreason.Inconnectionwithanyinjunctionsoughtorattempted by theCompany,theCompany shallberequiredtopostabondatleastequaltothegreaterof either:  (i)the  outstandingprincipal  amount  of  theNote;  and  (ii)the  market  value  ofthe ConversionSharessoughttobeconverted,exercisedorissued,basedonthesalepricepershare of Common Stock on the principal market on which it is traded. 7.   Delivery of Unlegended Shares.  a) Withinthree(3)businessdays(suchthirdbusinessdaybeingthe “UnlegendedSharesDeliveryDate”)afterthebusinessdayonwhichtheCompanyhas received (i) a notice that Conversion Shares, or anyother Common Stock held bythePurchaser hasbeensoldpursuanttoaregistrationstatementorRule144underthe1933Act,(ii)a representationthattheprospectusdeliveryrequirements,ortherequirementsofRule144,as applicableandifrequired,havebeensatisfied,(iii)theoriginalsharecertificatesrepresenting the shares of Common Stock that have been sold,and (iv) in the case of sales under Rule 144, customaryrepresentation letters of the Purchaser and, if required, Purchaser’s broker regarding compliancewiththerequirementsofRule144,theCompanyatitsexpense,(y)shalldeliver, andshallcauselegalcounselselectedbythePurchasertodelivertoitstransferagent(with copiestoPurchaser)anappropriateinstructionandopinionofsuchcounsel,directingthe 13 SPA – PRLX, T1, 2019-02-27  deliveryofsharesofCommonStockwithoutanylegendsincludingthelegendsetforthin Section4(h)above(the“UnlegendedShares”);and(z)causethetransmissionofthe certificates   representing   the   Unlegended   Shares   together   with   a   legended   certificate representing the balance of the submitted Common Stock certificate, if any, to the Purchaser at theaddressspecifiedinthenoticeofsale,viaexpresscourier,byelectronictransferorotherwise on or before the Unlegended Shares Delivery Date.  b) TheCompanyunderstandsthatadelayinthedeliveryoftheUnlegended ShareslaterthantheUnlegendedSharesDeliveryDatecouldresultineconomiclosstothe Purchaser.AscompensationtoPurchaserforsuchloss,theCompanyagreestopaylate payment fees (as liquidated damages and not as apenalty) to the Purchaser for late delivery of UnlegendedSharesintheamountof$250.00perbusinessdayaftertheUnlegendedShares DeliveryDate.Ifduringanythreehundredandsixty(360)dayperiod,theCompanyfailsto deliver Unlegended Shares as required bythis Section for an aggregate of thirty(30) days, then PurchaserorassigneeholdingSecuritiessubjecttosuchdefaultmay,atitsoption,requirethe Company to redeem all or any portion of the shares subject to such default at a price per share equaltothegreaterof(i)200%ofthemostrecentclosingpriceoftheCommonStockor(ii) the  parityvalue  of  the  Default  Sum  to  be  paid  (as  defined  in  Section  3.16  of  the  Note) (“Unlegended Redemption Amount”).  The Companyshall pay anypayments incurred under this Section in immediately available funds upon demand. 8.   ConditionstotheCompany’sObligationtoSell.TheobligationoftheCompany hereundertoissue andselltheNoteto thePurchaseratthe Closingissubject tothesatisfaction, at or before the Closing Date of each of the following conditions provided that these conditions arefor the Company’ssole benefitand may bewaived by the Company atany time in its sole discretion:  a) ThePurchasershallhaveexecutedthisAgreementanddeliveredthesame to the Company.  b) The Purchaser shall have delivered the Purchase Price to the Company.  c) TherepresentationsandwarrantiesofthePurchasershallbetrueandcorrect in all material respects asof the date when made and as of the Closing Date as though made at thattime(exceptforrepresentationsandwarrantiesthatspeakasofaspecificdate),andthe Purchaser  shall  have  performed,  satisfied  and  complied  in  all  material  respects  with  the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Purchaser at or prior to the Closing Date.  d) Nolitigation,statute,rule,regulation,executiveorder,decree,rulingor injunctionshallhavebeenenacted,entered,promulgatedorendorsedbyorinanycourtor governmentalauthorityofcompetentjurisdictionoranyself-regulatoryorganizationhaving authorityoverthematterscontemplatedherebywhichprohibitstheconsummationofanyofthe transactions contemplated by this Agreement. 9.   Conditions  to  The  Purchaser’s  Obligation  to  Purchase.  The  obligation  of  the PurchaserhereundertopurchasetheNoteattheClosingissubjecttothesatisfaction,ator 14 SPA – PRLX, T1, 2019-02-27  before the Closing Date of each of the following conditions, provided that these conditions are forthePurchaser’ssolebenefitandmaybewaivedbythePurchaseratanytimeinitssole discretion:  a) TheCompany shallhaveexecutedthisAgreementanddeliveredthesame to the Purchaser.  b) The Companyshall have delivered to the Purchaser the dulyexecuted Note (in such denominations as the Purchaser shall request) in accordance with Section 1 above.  c) TheIrrevocableTransferAgentInstructions,informandsubstance satisfactory to the Purchaser, shall have been delivered to andacknowledged in writing by the Company’sTransferAgent(acopyofwhichwrittenacknowledgmentshallbeprovidedto Purchaser prior to Closing).  d) TherepresentationsandwarrantiesoftheCompanyshallbetrueandcorrect in all material respects as of the date when made and as of the Closing Date as though made at suchtime(exceptforrepresentationsandwarrantiesthatspeakasofaspecificdate)andthe Company  shall  have  performed,  satisfied  and  complied  in  all  material  respects  with  the covenants, agreements and conditions required by this Agreement to be performed, satisfied or compliedwithbytheCompanyatorpriortotheClosingDate.ThePurchasershallhave receivedacertificateorcertificatesreasonablyrequestedbythePurchaserincluding,butnot limitedtocertificateswithrespecttotheCompany’sFormationDocuments,By-laws,and Board of Directors’ resolutions relating to the transactions contemplated hereby.  e) Nolitigation,statute,rule,regulation,executiveorder,decree,rulingor injunctionshallhavebeenenacted,entered,promulgatedorendorsedbyorinanycourtor governmentalauthorityofcompetentjurisdictionoranyself-regulatoryorganizationhaving authorityoverthematterscontemplatedherebywhichprohibitstheconsummationofanyofthe transactions contemplated by this Agreement.  f) Noeventshallhaveoccurredwhichcouldreasonably beexpectedtohave aMaterialAdverseEffectontheCompanyincludingbutnotlimitedtoachangeinthe1934 Act reporting status of the Company or the failure of the Company to be timely in its 1934 Act reporting obligations.  g) TheConversionSharesshallhavebeenauthorizedforquotationonthe OTCBB, OTCQB, and OTC Pink and trading of the Common Stock on the OTCBB, OTCQB, and OTC Pink shall not have been suspended by the SEC or the OTC Markets Group. 10. Governing Law; Miscellaneous.  a) GoverningLaw.ThisAgreementshallbegovernedbyandconstruedin accordancewiththelawsoftheStateofNevadawithoutregardtoprinciplesofconflictsoflaws thereoforanyotherState.  Anyactionbroughtbyanypartyagainstanyotherpartyhereto concerning thetransactionscontemplatedby thisAgreementshallbebroughtonly inthestate courts of NewYork or inthe federal courts located in the stateand county of NewYork.  The partiestothisAgreementhereby irrevocably waiveany objectiontojurisdictionandvenueof 15 SPA – PRLX, T1, 2019-02-27  any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venueorbasedupon forumnonconveniens.ThepartiesexecutingthisAgreementandother agreements  referred  to  herein  or  delivered  in  connection  herewith  on  behalf  of  the Companyagreetosubmittotheinpersonamjurisdictionofsuchcourtsandhereby irrevocablywaivetrialbyjury.  Theprevailingpartyshallbeentitledtorecoverfromthe otherpartyitsreasonableattorney’sfeesandcosts.  Intheeventthatanyprovisionofthis Agreementor anyotheragreementdeliveredinconnectionherewithisinvalidorunenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to theextentthatitmayconflicttherewithandshallbedeemedmodifiedtoconformwithsuch statuteorruleoflaw.  Anysuchprovisionwhichmayproveinvalidorunenforceableunder any lawshallnotaffectthevalidityorenforceabilityof anyotherprovisionofanyagreement.  Each partyheretoherebyirrevocablywaivespersonalserviceofprocessandconsentstoprocess being servedinany suit,actionorproceeding inconnectionwiththisAgreementorany other transaction document contemplated herebyby mailing a copythereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for noticestoitunderthisAgreement  andagreesthatsuchserviceshallconstitutegoodand sufficientserviceofprocessandnoticethereof.  Nothingcontainedhereinshallbedeemedto limit in anyway any right to serve process in any other manner permitted by law.  b) RemovalofRestrictiveLegends.  Intheeventthat Purchaserhasanyshares oftheCompany’sCommonStockbearinganyrestrictivelegends,andPurchaser,throughits counsel or other representatives, submits to the Transfer Agent anysuch shares for the removal oftherestrictivelegendsthereoninconnectionwithasaleofsuchsharespursuant to any exemptiontotheregistrationrequirementsundertheSecuritiesAct,andtheCompany and or its counsel refuses or fails for anyreason (except to the extent that such refusal or failure is based solely on applicable law that would prevent the removal of such restrictive legends) to render an opinion of counsel or any other documents or certificates required for the removal of therestrictivelegends,thentheCompany herebyagreesandacknowledgesthatthePurchaser is herebyirrevocablyand expressly authorized to have counsel to the Purchaser render any and all  opinions  and  other  certificates  or  instruments  which  maybe  required  for  purposes  of removing such restrictive legends, and the Company hereby irrevocably authorizes and directs theTransferAgentto,withoutanyfurtherconfirmationorinstructionsfromtheCompany,issue anysuchshareswithoutrestrictivelegendsasinstructedbythePurchaser,andsurrendertoa common carrier for overnight deliveryto the address as specified bythePurchaser, certificates, registeredinthenameofthePurchaseroritsdesignees,representingthesharesofCommon StocktowhichthePurchaserisentitled,withoutanyrestrictivelegendsandotherwisefreely transferable on the books and records of the Company.  c) FilingRequirements.FromthedateofthisAgreementuntiltheNotesare nolongeroutstanding,theCompanywilltimelyandvoluntarilycomplywithallreporting requirementsthatareapplicabletoanissuerwithaclassofsharesregisteredpursuanttoSection 12(g)ofthe1934Act,whetherornottheCompany  isthensubjecttosuchreporting requirements,andcomplywithallrequirements  relatedtoanyregistrationstatementfiled pursuant to this Agreement.  The Companywill use reasonable efforts not to take any action or fileanydocument(whetherornotpermittedbythe1933Actorthe1934Actortherules thereunder)toterminateorsuspendsuchregistrationortoterminateorsuspenditsreporting andfiling obligationsundersaidactsuntilthe Notesarenolongeroutstanding.TheCompany 16 SPA – PRLX, T1, 2019-02-27  will maintain the quotation or listing of its Common Stock on the OTCBB, OTCQB, NYSE, or NASDAQ  Stock  Market  (whichever  of  the  foregoing  is  at  the  time  the  principal  trading exchangeormarketfortheCommonStock(the“PrincipalMarket”),andwillcomply inall respectswiththeCompany’sreporting,filingandotherobligationsunderthebylawsorrules of the Principal Market, as applicable. The Company will provide Purchaser with copies of all notices it receives notifyingthe Companyof the threatened and actual delistingof the Common Stockfromany PrincipalMarket.  AsofthedateofthisAgreementandtheClosingDate,the OTCQB,isthePrincipalMarket.UntiltheNoteisnolongeroutstanding,theCompanywill continue the listing or quotation of the Common Stock on aPrincipal Market andwill comply inallrespectswiththeCompany’sreporting,filingandotherobligationsunderthebylawsor rules of the Principal Market.  d) FeesandExpenses.OnorpriortotheClosing,theCompany shallpay or reimbursetoPurchaseranon-refundable,non-accountablesumequalto$4,440.00asandfor the fees, costs and expenses (including without limitation legal fees and disbursements and due diligence  and  administrative  expenses)  incurred  by  the  Purchaser  in  connection  with  the Purchaser’s  duediligenceand  negotiation,  preparationand  executionof  theTransaction DocumentsandconsummationoftheTransactions.ThePurchasermaywithholdandoffsetthe balance of such amount from the payment of its Purchase Price otherwise payable hereunder at Closing,whichoffsetshallconstitutepartialpaymentofsuchPurchasePriceinanamountequal to such offset.  Except as expresslyset forth in this Agreement orthe Note to the contrary, each party shall pay thefeesand expenses of its advisers, counsel, accountants and other experts, if any,andallotherexpensesincurredbysuchpartyincidenttothenegotiation,preparation, execution,deliveryandperformanceofthisAgreement.TheCompanyshallpayalltransfer agent fees, stamp taxes and other taxes and duties levied in connection with the deliveryof any Securities to the Purchaser.  e) Usury.Totheextentitmaylawfullydo so,theCompanyherebyagreesnot to insist upon or plead or in any manner whatsoever claim, and will resist any and all efforts to becompelledtotakethebenefitoradvantageof,usury lawswhereverenacted,noworatany time hereafter in force, in connection with any claim, action or proceeding that may be brought by the Purchaser in order to enforce any right or remedy under the Note.  Notwithstanding any provisiontothecontrarycontainedinhereinorundertheNote,itisexpresslyagreedand providedthatthetotalliabilityoftheCompanyundertheNoteforpaymentsinthenatureof interest  shall  not  exceed  the  maximum  lawful  rate  authorized  under  applicable  law  (the “Maximum Rate”), and, without limiting the foregoing, in no event shall any rate of interest or  default interest, or both of them, when aggregated with any other sums in the nature of interest thattheCompanymaybeobligatedtopayundertheNoteorhereinexceedsuchMaximum Rate.Itisagreedthatifthemaximumcontractrateofinterestallowedby lawandapplicable to the Note is increased or decreased by statute or any official governmental action subsequent tothedatehereof,thenewmaximumcontractrateofinterestallowedbylawwillbethe Maximum Rate applicable to the Note from the effective date forward, unless such application isprecludedbyapplicablelaw.Ifunderanycircumstanceswhatsoever,interestinexcessof theMaximumRateispaidbytheCompanytothePurchaserwithrespecttoindebtedness evidencedbytheNote,suchexcessshallbeappliedbythePurchasertotheunpaidprincipal balance of any such indebtedness or be refunded to the Company, the manner of handling such excess to be at the Purchaser’s election. 17 SPA – PRLX, T1, 2019-02-27    f) Headings.Theheadings ofthisAgreement are for convenienceof reference only and shall not form part of, or affect the interpretation of, this Agreement.  g) Severability. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperativetotheextentthatitmayconflicttherewithandshallbedeemedmodifiedtoconform withsuchstatuteorruleoflaw.Anyprovisionhereofwhichmayproveinvalidorunenforceable under any law shall not affect the validity or enforceability of any other provision hereof.  h) EntireAgreement;Amendments.ThisAgreementandtheinstruments referencedhereincontaintheentireunderstandingofthepartieswithrespecttothematters coveredhereinandthereinand,exceptasspecificallysetforthhereinortherein,neitherthe Company nor the Purchaser makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the Purchaser.  i) Notices.  All  notices,  demands,  requests,  consents,  approvals,  and  other communicationsrequiredorpermittedhereundershallbeinwritingand,unlessotherwise specifiedherein,shallbe:(i)personallyserved,(ii)depositedinthemail,registeredorcertified, returnreceiptrequested,postageprepaid,(iii)deliveredbyreputableaircourierservicewith chargesprepaid,or(iv)transmittedbyhanddelivery,telegram,emailorfacsimile,addressed assetforthbelowortosuchotheraddressassuchparty shallhavespecifiedmostrecently by written notice. Anynotice or other communication required or permitted to be given hereunder shallbedeemedeffective(a)uponhanddeliveryordeliverybyemailorfacsimilewithaccurate confirmationgeneratedbythetransmittingfacsimilemachineorcomputer,attheaddress,email addressorfacsimilenumberdesignatedbelow(ifdeliveredonabusinessdayduringnormal businesshourswheresuchnoticeistobereceived),orthefirstbusinessdayfollowingsuch delivery(ifdeliveredotherthanonabusinessdayduringnormalbusinesshourswheresuch noticeistobereceived)or(b)onthesecondbusinessdayfollowingthedateofmailingby express courier service, fullyprepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:  Purchaser: EMA Financial, LLC 40 Wall Street, 17th Floor New York, NY 10005 Attn: Jamie Beitler jbeitler@emafin.com  Company: Parallax Health Sciences, Inc. 1327 Ocean Ave, Suite B Santa Monica, CA 90401 Attn: Paul R. Arena, CEO Email: ________________ Fax: ________________ Each party shall provide notice to the other party of any change in address. 18 SPA – PRLX, T1, 2019-02-27    j) SuccessorsandAssigns.ThisAgreementshallbebindinguponandinure tothebenefitofthepartiesandtheirsuccessorsandassigns.NeithertheCompanynorthe PurchasershallassignthisAgreementorany rightsorobligationshereunderwithouttheprior written  consent  of  the  other.  Notwithstanding  the  foregoing,  subject  to  Section  2(f),  the PurchasermayassignitsrightshereundertoanypersonthatpurchasesSecuritiesinaprivate transactionfromthePurchaserortoanyofits“affiliates,”asthattermisdefinedunderthe1934 Act, without the consent of the Company.  k) Third PartyBeneficiaries. This Agreement is intended for the benefit of the partiesheretoandtheirrespectivepermittedsuccessorsandassigns,andisnotforthebenefit of, nor may any provision hereof be enforced by, any other person.  l) Survival.  The  representations  and  warranties  of  the  Company  and  the agreementsandcovenantssetforthinthisAgreementshallsurvivetheClosinghereunder notwithstandinganyduediligenceinvestigationconductedbyoronbehalfofthePurchaser. TheCompanyagreestoindemnifyandholdharmlessthePurchaserandalltheirofficers, directors,employeesand agentsforlossordamagearisingasaresultoforrelatedtoanybreach orallegedbreachbythePurchaserofanyofitsrepresentations,warrantiesandcovenantsset forthinthisAgreementoranyofitscovenantsand obligationsunderthisAgreement,including advancement of expenses as they are incurred.  m) FurtherAssurances.Eachpartyshalldoandperform,orcausetobedone andperformed,allsuchfurtheractsandthings,andshallexecuteanddeliverallsuchother agreements, certificates, instruments and documents, as the other partymay reasonablyrequest in  order  to  carry  out  the  intent  and  accomplish  the  purposes  of  this  Agreement  and  the consummation of the transactions contemplated hereby.  n) No  Strict  Construction.  The  language  used  in  this  Agreement  will  be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.  o) Remedies.TheCompanyacknowledgesthatabreachbyitofitsobligations hereunderwillcauseirreparableharmtothePurchaserbyvitiatingtheintentandpurposeofthe transaction contemplatedhereby. Accordingly, the Company acknowledges that the remedy at lawforabreachofitsobligationsunderthisAgreementwillbeinadequateandagrees,inthe eventofabreachorthreatenedbreachbytheCompanyoftheprovisionsofthisAgreement, thatthePurchasershallbeentitled,inadditiontoallotheravailableremediesatlaworinequity, andinadditiontothepenaltiesassessableherein,toaninjunctionorinjunctionsrestraining, preventingorcuringanybreachofthisAgreementandtoenforcespecificallythetermsand provisionshereof,withoutthenecessityofshowingeconomiclossandwithoutanybondor other security being required.  p) Counterparts.     ThisAgreementmaybeexecutedinanynumberof counterparts, each ofwhich when soexecutedanddeliveredshall be deemed to bean original andallofwhichtogethershallbedeemedtobeoneandthesameagreement.Anysignature 19 SPA – PRLX, T1, 2019-02-27  transmittedbyfacsimile,e-mail,orotherelectronicmeansshallbedeemedtobeanoriginal signature. [Remainder of Page Intentionally Left Blank] 20 SPA – PRLX, T1, 2019-02-27  INWITNESSWHEREOF,theundersignedPurchaserandtheCompany  havecausedthis Agreement to be duly executed as of the date first above written. PARALLAX HEALTH SCIENCES, INC. By: Name: Paul R. Arena Title: CEO EMA FINANCIAL, LLC By: Name:Jamie Beitler Title:Authorized Signatory GUARANTY EachoftheundersignedsubsidiariesoftheCompanyjointlyandseverally,absolutely, unconditionallyandirrevocably,guarantees  tothePurchaserandtheir  respectivesuccessors, indorsees,transfereesandassigns,thepromptandcompletepaymentandperformancebythe Company whendue(whetheratthestatedmaturity,by accelerationorotherwise)ofallamounts dueunder,andallotherobligationsunder,theNote.Eachsuchsubsidiary’sliabilityunderthis Guaranty shall be unlimited, open and continuous for so long as this Guaranty remains in force. PARALLAXHEALTH  MANAGEMENT,      PARALLAX COMMUNICATIONS,  INC. INC.  By: By:    Print Name: Print Name:  Title: Title: PARALLAX BEHAVIORAL HEALTH, INC.     PARALAX DIAGNOSTICS, INC.  By: By:    Print Name: Print Name:  Title: Title:  SPA – PRLX, T1, 2019-02-27 21